Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD Moves The Needle To High-Growth Segments

Exploiting The Trend To Pharmacy Automation And Remote Patient Care

Executive Summary

Becton Dickinson is investing in high-growth segments and is on a mission to simplify its business. CEO Tom Polen’s 2025 strategy targets 25% operating margin from both innovations and durable core business combined, as senior BD executives told In Vivo during a break at J.P. Morgan 2024.

You may also be interested in...



The Buck Stops Here: BD CEO Tom Polen On How To Make A Medtech Company Succeed

BD CEO Tom Polen is at the bottom of the pyramid – it’s where he wants to be and is best positioned to continue the company’s transition to focusing on high-growth spaces, as set out in the BD2025 strategy.

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Launch Of Team-AB Offers United Voice For UK Approved Bodies

Forum officially unveiled on 19 February to represent growing band of organizations designated against the UKCA mark.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT154392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel